Oruka Therapeutics宣布2亿美元私人融资

Oruka Therapeutics (NASDAQ:ORKA) is looking to raise approximately $200M from a private investment in public equity (PIPE) financing.

Oruka is selling 5.6M shares of its common stock at $23 each, 2,439 shares of its Series A non-voting convertible preferred stock at $23,000 per share and pre-funded warrants to purchase 680,000 shares of common stock at $22.999 per pre-funded warrant.

The pre-funded warrants have an exercise price of $0.001 per share. The shares of Series A Preferred Stock issued in the PIPE financing are convertible into 2,439,000 shares of common stock, with each share of Series A Preferred Stock being convertible into 1,000 shares of common stock.

The company plans to use the net proceeds from the financing, together with existing cash, cash equivalents, and marketable securities, to support research and development, general corporate expenses, and working capital needs. Oruka Therapeutics (ORKA) expects that its cash will fund its operating plan through 2027.

More on ARCA biopharma

• ARCA biopharma approves 1-for-12 reverse stock split
• Historical earnings data for ARCA biopharma
• Financial information for ARCA biopharma